FDA-Cleared Device vs. FDA-Approved Biologic: What the Difference Means When Choosing a Stem Cell Clinic

Many stem cell clinics process a patient's own fat or bone marrow tissue using specialized equipment, and some advertise that this equipment is "FDA-cleared." That statement can be entirely true — and still have nothing to do with whether the treatment itself is approved, safe, or effective. This article explains the real, legally meaningful difference between an FDA-cleared device and an FDA-approved biologic, why clinics sometimes blur the two, and what questions can help you tell them apart.

Two Very Different FDA Words: "Cleared" and "Approved"

The FDA uses specific, legally distinct language for different kinds of products, and the differences aren't just semantic. A medical device can receive what's called 510(k) clearance, which means the FDA has determined it's "substantially equivalent" to an existing, legally marketed device in terms of safety for its intended use. According to the FDA's own guidance on the 510(k) program, this is a premarket notification process focused on comparing a new device to a predicate device — it is explicitly not a determination that the device, or anything made using it, is safe and effective in the way a new drug or biological product is evaluated. A biologic or drug, by contrast, goes through an entirely separate approval pathway — a New Drug Application or Biologics License Application — that requires clinical trial evidence of safety and effectiveness for a specific use. The FDA deliberately uses different words — "cleared" for devices, "approved" for drugs and biologics — because these represent genuinely different regulatory standards.

What a Point-of-Care Processing Device Actually Is

Many stem cell and regenerative medicine clinics use point-of-care systems — equipment that mechanically washes, filters, or centrifuges a patient's own fat or bone marrow tissue in order to concentrate certain cell populations before the material is reinjected elsewhere in the body. Some of these processing systems have received FDA 510(k) clearance as devices. That clearance says something real about the device itself — that the agency considers it comparably safe to other cleared equipment used for similar mechanical processing. It says nothing, on its own, about whether the biological product that comes out of the device — the processed cells — has been shown in controlled trials to safely and effectively treat the condition it's being marketed for.

Why the Device Being Cleared Doesn't Mean the Treatment Is Approved

This is the crux of the confusion, and it has a real regulatory basis. The processed cells themselves are separately regulated by the FDA as human cells, tissues, and cellular and tissue-based products (HCT/Ps) under a distinct set of federal rules. A narrow category of HCT/Ps — those that are only minimally manipulated, intended for a function the tissue normally performs ("homologous use"), and in some cases used within the same surgical procedure — can be used without the FDA premarket approval required of a drug. Everything else requires the same kind of rigorous Biologics License Application approval process used for any other new biological therapy. A federal appeals court addressed exactly this distinction in United States v. US Stem Cell Clinic, LLC, ruling in 2021 that a clinic's adipose-derived cell product did not qualify for that narrow exemption and required FDA drug approval it did not have — a ruling that turned on the biological product's regulatory status, not on whether the processing equipment itself was a legitimate, cleared device.

A Pattern Regulators Have Flagged Before

This isn't a hypothetical concern. Over the past decade, the FDA and the Federal Trade Commission have taken public enforcement action against multiple U.S. stem cell clinics for marketing unapproved, minimally regulated cell products as though they were established, approved treatments — including formal FDA warning letters citing manufacturing and regulatory violations, and FTC settlements addressing deceptive advertising of unproven treatment claims. The FDA's own consumer-facing guidance on regenerative medicine therapies separately warns that being registered or listed with the FDA — a basic administrative step many HCT/P establishments take — does not mean a product is legally marketed or has been evaluated for safety and effectiveness. The common thread across these cases is the same one at the center of the device-versus-biologic distinction: a scientific-sounding or regulatory-sounding term, used imprecisely, can make an unapproved treatment sound more vetted than it actually is.

Questions Worth Asking

Before assuming a "FDA-cleared" claim means more than it does, it's reasonable to ask a clinic directly: is it the processing device that's cleared, or has the specific cell product and its intended use received FDA approval through a Biologics License Application? Has the treatment been tested in a registered, published clinical trial for the condition being treated, rather than just processed with cleared equipment? And is the clinic able to point to the specific FDA approval, if any exists, for the actual treatment being offered — not just the hardware used to prepare it?

Bottom Line

"FDA-cleared" and "FDA-approved" sound similar, and marketing materials don't always go out of their way to clarify the difference — but they describe two entirely different kinds of regulatory review, applied to two entirely different things. A clinic's processing equipment being a legitimately cleared medical device says nothing about whether the treatment it produces has been proven safe and effective. Understanding that distinction is one of the more reliable ways to evaluate a clinic's claims on their own regulatory merits, rather than on how official they sound.